We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+15.42%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$542M
AUM Growth
+$154M
Cap. Flow
+$142M
Cap. Flow %
26.23%
Top 10 Hldgs %
64.51%
Holding
60
New
22
Increased
12
Reduced
3
Closed
21

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$37.3M
2
MRK icon
Merck
MRK
+$20.1M
3
VTRS icon
Viatris
VTRS
+$18M
4
ABLX
Ablynx NV
ABLX
+$14.4M
5
SHPG
Shire pic
SHPG
+$13.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$20.3M
2
GSK icon
GSK
GSK
+$14.5M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$12.9M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$10.7M
5
AKAO
Achaogen Inc
AKAO
+$9.21M

Sector Composition

Rank Sector Weight
1 Healthcare 48.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRA icon
26
Atara Biotherapeutics
ATRA
$71.2M
$5.19M 0.96%
+11,466
New +$4.23M
CBAY
27
DELISTED
Cymabay Therapeutics
CBAY
$4.94M 0.91%
536,568
+521,568
+3,477% +$4.46M
SPPI
28
PUT
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$4.91M 0.91%
+259,300
New +$4.7M
GYRE icon
29
Gyre Therapeutics
GYRE
$662M
$4.24M 0.78%
+41,490
New +$2.12M
AVDL
30
DELISTED
Avadel Pharmaceuticals
AVDL
$4.15M 0.76%
+505,921
New +$4.74M
TSRO
31
PUT
DELISTED
TESARO, Inc.
TSRO
$4.14M 0.76%
50,000
– –
CTMX icon
32
CytomX Therapeutics
CTMX
$705M
$3.8M 0.7%
+179,870
New +$3.73M
OTIC
33
DELISTED
Otonomy, Inc.
OTIC
$3.35M 0.62%
+602,748
New +$2.62M
TXMD icon
34
TherapeuticsMD
TXMD
$23.8M
$3.19M 0.59%
+10,567
New +$2.94M
ANIP icon
35
ANI Pharmaceuticals
ANIP
$1.77B
$2.7M 0.5%
+41,905
New +$2.61M
KALV
36
DELISTED
KalVista Pharmaceuticals
KALV
$1.76M 0.33%
+180,794
New +$1.88M
LRMR icon
37
Larimar Therapeutics
LRMR
$416M
$792K 0.15%
+14,286
New +$644K
TGTX icon
38
TG Therapeutics
TGTX
$8.58B
$246K 0.05%
+30,000
New +$262K
VTGN icon
39
VistaGen Therapeutics
VTGN
$9.29M
$154K 0.03%
4,604
– –
ABEO icon
40
CALL
Abeona Therapeutics
ABEO
$345M
– –
-12,000
Closed -$5.12M
ACRS icon
41
Aclaris Therapeutics
ACRS
$730M
– –
-416,312
Closed -$10.7M
GSK icon
42
GSK
GSK
$103B
– –
-286,442
Closed -$14.5M
INDP icon
43
Indaptus Therapeutics
INDP
$348M
– –
-123
Closed -$2.47M
MDGL icon
44
Madrigal Pharmaceuticals
MDGL
$12.6B
– –
-28,536
Closed -$1.28M
NERV icon
45
Minerva Neurosciences
NERV
$188M
– –
-67,112
Closed -$4.08M
SUPN icon
46
Supernus Pharmaceuticals
SUPN
$2.68B
– –
-132,270
Closed -$5.29M
TEVA icon
47
PUT
Teva Pharmaceuticals
TEVA
$35.9B
– –
-1,000,000
Closed -$17.6M
SGEN
48
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-373,000
Closed -$20.3M
PRTK
49
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-242,300
Closed -$6.08M
SIOX
50
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-5,000
Closed -$275K
1
2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Nexthera Capital held 60 positions worth $542M, up 40% from $389M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Nexthera Capital deployed $142M of net new capital in Q4 2017, opening 22 new positions and adding to 12 existing holdings. Its largest new stake was Allergan plc: 207,871 shares worth $34M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 50% a quarter earlier.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $4.57M trimmed.

  • Nexthera Capital's largest Q4 2017 buy was Allergan plc: 207,871 shares worth $34M.
  • Nexthera Capital added most to Shire pic in Q4 2017, an estimated $13.7M increase.
  • Nexthera Capital's biggest Q4 2017 reduction was Immunomedics Inc, cutting an estimated $4.57M.
  • Nexthera Capital fully exited Seagen Inc. Common Stock in Q4 2017, selling an estimated $20.3M.
  • Nexthera Capital's ten largest holdings make up 65% of its $542M portfolio in Q4 2017.
  • Nexthera Capital opened 22 new positions and closed 21 in Q4 2017.
  • Nexthera Capital's portfolio value rose 40% quarter-over-quarter to $542M.

Based on Nexthera Capital's 13F filing for Q4 2017, filed 14 Feb 2018.